Tuesday 17 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.38
0.24
−1.22%
Follow BRVE
Alert me
Where the cash went Twelve months to 30 September 2026
Free cash flow was −$47.8M: capital expenditures were more than operating cash flow. Cash rose by $53.8M. Lines the picture does not name came to −$390.9M. What is a cash flow statement?
- Free cash flow
- −$47.8M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- +$53.8M over the period
| Operating cash flow | 0.0 |
|---|---|
| Free cash flow | 0.0 |
| Shares issued, net | +0.5 |
| Other | −0.4 |
| Change in cash | 0.1 |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | |
|---|---|---|---|---|
Net Income |
(62.22) | (94.84) | (80.23) | (66.05) |
Non Cash Items (Other) |
70.06 | 61.97 | 60.98 | — |
Change in payables and accrued liability |
6.65 | 3.48 | 0.48 | — |
Change in other assets and liabilities |
(10.22) | (0.58) | (0.46) | — |
Operating Cash Flow |
(47.78) | (24.15) | (7.20) | (2.01) |
Other investing activities |
(3.83) | — | — | — |
Investing cash flow |
(386.31) | — | — | — |
Financing cash flow |
487.86 | 183.58 | — | — |
Change in Cash |
53.76 | 122.83 | 80.58 | 89.16 |
Ending Cash |
142.92 | 211.99 | — | — |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
(0.06) | 5.87 | 8.95 | 1.62 |
Issuance/Purchase of Shares |
492.39 | 184.34 | — | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 12 Nov 2026